Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study

  • de Gonzalo Calvo, David
  • Molinero, Marta
  • Benítez, Iván D.
  • Perez Pons, Manel
  • García Mateo, Nadia
  • Ortega, Alicia
  • Postigo, Tamara
  • García Hidalgo, María C.
  • Belmonte, Thalía
  • Rodríguez Muñoz, Carlos
  • González, Jessica
  • Torres, Gerard
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Estella García, Ángel
  • Tamayo Lomas, Luis
  • Martínez de la Gándara, Amalia
  • Socias, Lorenzo
  • Peñasco, Yhivian
  • de la Torre, María del Carmen
  • Bustamante Munguira, Elena
  • Gallego Curto, Elena
  • Martínez Varela, Ignacio
  • Martín Delgado, María Cruz
  • Vidal Cortés, Pablo
  • López Messa, Juan
  • Pérez García, Felipe
  • Caballero, Jesús
  • Añón, José Manuel
  • Loza Vázquez, Ana
  • Carbonell, Nieves
  • Marin Corral, Judith
  • Jorge García, Ruth Noemí
  • Barberà, Carmen
  • Ceccato, Adrián
  • Fernández Barat, Laia
  • Ferrer, Ricard
  • García Gasulla, Dario
  • Lorente Balanza, Jose Ángel
  • Menéndez, Rosario
  • Motos, Ana
  • Peñuelas, Oscar
  • Riera, Jordi
  • Bermejo Martin, Jesús F.
  • Torres, Antoni
  • Barbé, Ferrán
Background: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU. Methods: This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group. Results: Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR < 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). Kaplan‒Meier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also improved the prognostic value of APACHE-II, SOFA and the clinical model. The association between the classifier and mortality persisted even after multivariable adjustment. The functional analysis reported biological pathways involved in SARS-CoV infection and inflammatory, fibrotic and transcriptional pathways. Conclusions: A blood miRNA classifier improves the early prediction of fatal outcomes in critically ill COVID-19 patients., 11 páginas
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Anticoagulant Treatment in Severe ARDS COVID-19 Patients

  • Ceccato, Adrian|||0000-0001-9454-062X
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Campaña-Duel, Elena|||0000-0002-0658-6255
  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Morales-Quinteros, Luis|||0000-0002-8937-9824
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
Patients with COVID-19 may complicate their evolution with thromboembolic events. Incidence of thromboembolic complications are high and also, patients with the critically-ill disease showed evidence of microthrombi and microangiopathy in the lung probably due to endothelial damage by directly and indirectly injured endothelial and epithelial cells. Pulmonary embolism, deep venous thrombosis and arterial embolism were reported in patients with COVID-19, and several analytical abnormal coagulation parameters have been described as well. D-dimer, longer coagulation times and lower platelet counts have been associated with poor outcomes. The use of anticoagulation or high doses of prophylactic heparin is controversial. Despite the use of anticoagulation or high prophylactic dose of heparin have been associated with better outcomes in observational studies, only in patients with non-critically ill disease benefits for anticoagulation was observed. In critically-ill patient, anticoagulation was not associated with better outcomes. Other measures such as antiplatelet therapy, fibrinolytic therapy or nebulized anticoagulants are being studied in ongoing clinical trials.